We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current AWKNF market cap is 3.01M. The company's latest EPS is CAD -0.2313 and P/E is -0.35.
Year End 31 January 2023 | 2022 | 2023 |
---|---|---|
CAD ($) | CAD ($) | |
Total Revenue | 246k | 1.5M |
Operating Income | -9.78M | -9.19M |
Net Income | -15.95M | -9.14M |
Year End 31 January 2023 | 2022 | 2023 |
---|---|---|
CAD ($) | CAD ($) | |
Total Assets | 6.88M | 4.39M |
Total Liabilities | 3.85M | 4.44M |
Total Equity | 3.02M | -49k |
Year End 31 January 2023 | 2022 | 2023 |
---|---|---|
CAD ($) | CAD ($) | |
Operating | -8.59M | -7.36M |
Investing | -1.69M | -95k |
Financing | 11.5M | 6.4M |
Market Cap | 3.01M |
Price to Earnings Ratio | -0.35 |
Price to Sales Ratio | 2.12 |
Price to Cash Ratio | 5.76 |
Price to Book Ratio | -64.52 |
Dividend Yield | - |
Shares Outstanding | 39.52M |
Average Volume (1 week) | 13k |
Average Volume (1 Month) | 9.15k |
52 Week Change | -53.54% |
52 Week High | 0.26 |
52 Week Low | 0.0422 |
Spread (Intraday) | 0.06 (46.27%) |
Company Name | Awakn Life Sciences Corporation (QB) |
Address |
301‐217 queen street w toronto, ontario M5V 0R2 |
Website | https://www.awaknlifesciences.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions